Protection of ischemic myocardium in dogs using intracoronary 2,3-butanedione monoxime (BDM)
Background. – Actomyosin ATPase is one of the major ATP consuming enzymes in the myocardium. We tested whether 2,3-butanedione monoxime (BDM), a reversible inhibitor of actomyosin ATPase, given before coronary occlusion, limits infarct size in anesthetized open-chest dogs. Methods and results. – Aft...
Gespeichert in:
Veröffentlicht in: | Journal of molecular and cellular cardiology 2003-02, Vol.35 (2), p.165-176 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background. –
Actomyosin ATPase is one of the major ATP consuming enzymes in the myocardium. We tested whether 2,3-butanedione monoxime (BDM), a reversible inhibitor of actomyosin ATPase, given before coronary occlusion, limits infarct size in anesthetized open-chest dogs.
Methods and results. –
After circumflex artery catheterization using fluoroscopic guidance, BDM (125 mM) or buffer vehicle was infused (12.0 ml/min) for 20 min (BDM-20,
n = 5 and Buffer-20,
n = 6) or for 5 min (BDM-5,
n = 6 and Buffer-5,
n = 6) prior to 60 min of ischemia and 3 h of reperfusion. BDM administration increased subendocardial blood flow 271% above baseline flow (radioactive microspheres), and systolic wall thickening was converted to wall bulging (wall thickening by sonomicrometry was –27 ± 29% and –22 ± 13% of baseline in BDM-20 and BDM-5, respectively). Adjusted mean infarct size (% area-at-risk) was 11.0 ± 2.8% and 11.9 ± 2.6% in BDM-20 and BDM-5 vs. 20.2 ± 2.5% and 20.5 ± 2.5% in Buffer-20 and Buffer-5 (ancova,
P |
---|---|
ISSN: | 0022-2828 1095-8584 |
DOI: | 10.1016/S0022-2828(02)00303-6 |